New pill targets rare lung cancer mutations in early trial
NCT ID NCT07117890
First seen Jan 04, 2026 · Last updated May 19, 2026 · Updated 19 times
Summary
This study tests a daily pill called sunvozertinib in 34 adults with advanced non-small cell lung cancer that has certain uncommon EGFR gene changes. Participants have not had prior cancer treatment. The main goal is to see how many people's tumors shrink, and how long that lasts. This is a phase 2 trial, so it is still early, but it offers a potential new option for people with these rare mutations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan university shanghai cancer center
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.